- List
- By Topic
- On Map
- Search Details

cannabidiol (177 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03102918 | Completed Has Results |
Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
10 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT03102918 | 2015P002013 | CBD | February 20, 2016 | August 30, 2017 | August 30, 2017 | April 6, 2017 | January 25, 2019 | January 25, 2019 |
|
|
2 | NCT03634189 | Not yet recruiting | Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
20 | All | 30 Years to 75 Years (Adult, Older Adult) | NCT03634189 | CAPITAL-AC | CAPITAL-AC | March 1, 2019 | September 1, 2019 | March 1, 2020 | August 16, 2018 | November 14, 2018 | |||
3 | NCT02548559 | Recruiting | Sublingual Cannabidiol for Anxiety |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
16 | All | 18 Years and older (Adult, Older Adult) | NCT02548559 | 2015P000959 | August 14, 2018 | August 2019 | August 2019 | September 14, 2015 | August 15, 2018 |
|
|||
4 | NCT03310593 | Recruiting | Cannabidiol as an Adjunctive Treatment for Bipolar Depression |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
100 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03310593 | 63811317300005327 | CBDBD | November 1, 2017 | October 2019 | February 2020 | October 16, 2017 | December 18, 2018 |
|
||
5 | NCT02332655 | Active, not recruiting | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
10 | All | 1 Month to 45 Years (Child, Adult) | NCT02332655 | IRB00029264 | December 2014 | June 2019 | June 2019 | January 7, 2015 | January 8, 2019 |
|
|||
6 | NCT03355300 | Recruiting | Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
30 | All | 3 Years to 17 Years (Child) | NCT03355300 | INS011-17-113 | February 20, 2018 | November 2019 | November 2019 | November 28, 2017 | February 5, 2019 |
|
|||
7 | NCT03336242 | Recruiting | Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
30 | All | 3 Years to 17 Years (Child) | NCT03336242 | INS011-17-103 | December 15, 2017 | February 2019 | February 2019 | November 8, 2017 | February 5, 2019 |
|
|||
8 | NCT03248167 | Not yet recruiting | Cannabidiol as a Treatment for AUD Comorbid With PTSD |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / NIH |
|
|
50 | All | 18 Years and older (Adult, Older Adult) | NCT03248167 | 17-00949 | November 15, 2018 | August 31, 2019 | August 31, 2019 | August 14, 2017 | April 6, 2018 |
|
|||
9 | NCT01596075 | Unknown † | Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT01596075 | 0388-11-RMC | July 2012 | July 2015 | May 10, 2012 | September 11, 2012 |
|
||||
10 | NCT03164512 | Recruiting | The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
24 | All | 18 Years to 45 Years (Adult) | NCT03164512 | IRB00128331 | June 1, 2018 | August 30, 2019 | August 30, 2019 | May 23, 2017 | July 16, 2018 |
|
|||
11 | NCT02324673 | Completed Has Results |
Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
61 | All | 1 Year to 17 Years (Child) | NCT02324673 | INS011-14-029 | April 13, 2015 | May 9, 2016 | May 9, 2016 | December 24, 2014 | June 23, 2017 | June 23, 2017 |
|
||
12 | NCT02660255 | Available | Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy |
|
|
Expanded Access |
|
Other / Industry | All | 1 Year to 60 Years (Child, Adult) | NCT02660255 | 719-15-FB | CBD | February 2016 | May 2018 | May 2018 | January 21, 2016 | May 3, 2017 | |||||||
13 | NCT01385124 | Unknown † | Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
30 | All | 18 Years and older (Adult, Older Adult) | NCT01385124 | 6276 | September 2012 | December 2015 | June 29, 2011 | June 19, 2015 |
|
||||
14 | NCT03458416 | Recruiting | A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
66 | All | 8 Years to 17 Years (Child) | NCT03458416 | INS011-17-115 | September 6, 2018 | May 2020 | May 2020 | March 8, 2018 | February 5, 2019 |
|
|||
15 | NCT03676049 | Available | Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use) |
|
|
Expanded Access
|
|
Other | All | 5 Years to 19 Years (Child, Adult) | NCT03676049 | 2017-0259 | September 18, 2018 | September 18, 2018 |
|
||||||||||
16 | NCT02286986 | Active, not recruiting | Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
25 | All | 2 Years to 25 Years (Child, Adult) | NCT02286986 | IND 70871 | September 2014 | January 2019 | April 2019 | November 10, 2014 | July 19, 2018 |
|
|||
17 | NCT01311778 | Completed | Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
18 | All | 21 Years to 65 Years (Adult, Older Adult) | NCT01311778 | R21DA027781 | February 2010 | October 2011 | October 2011 | March 10, 2011 | March 22, 2013 |
|
|||
18 | NCT01037322 | Completed | Cannabidiol for Inflammatory Bowel Disease |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
20 | All | 20 Years to 80 Years (Adult, Older Adult) | NCT01037322 | canabidiol1 | January 2010 | September 2012 | September 2012 | December 23, 2009 | April 16, 2013 |
|
|||
19 | NCT02551731 | Terminated Has Results |
Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
9 | All | 6 Months to 36 Months (Child) | NCT02551731 | INS011-15-054 | January 27, 2016 | September 6, 2016 | September 6, 2016 | September 16, 2015 | September 19, 2018 | September 19, 2018 |
|
||
20 | NCT03014440 | No longer available | Study of Cannabidiol for Drug-Resistant Epilepsies |
|
|
Expanded Access |
|
Other | All | 1 Year to 20 Years (Child, Adult) | NCT03014440 | 13-010562 | January 9, 2017 | April 4, 2017 | |||||||||||
21 | NCT03471559 | Recruiting | Cannabidiol - an in Vivo Innovative Drug Delivery Study |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
24 | All | 18 Years to 85 Years (Adult, Older Adult) | NCT03471559 | CBD-DDS | December 10, 2018 | May 31, 2019 | August 31, 2019 | March 20, 2018 | December 13, 2018 |
|
|||
22 | NCT02318563 | Withdrawn | Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
0 | All | 1 Year to 30 Years (Child, Adult) | NCT02318563 | INS011-14-025 | December 30, 2017 | June 17, 2018 | June 17, 2018 | December 17, 2014 | January 4, 2018 | ||||
23 | NCT03252756 | Not yet recruiting | Effects of Cannabidiol in Alcohol Use Disorder |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / NIH |
|
|
40 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT03252756 | 17-01001 | April 15, 2019 | November 2019 | January 2020 | August 17, 2017 | January 25, 2019 |
|
|||
24 | NCT02318537 | Withdrawn | Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
0 | All | 2 Years to 30 Years (Child, Adult) | NCT02318537 | INS011-14-024 | December 30, 2017 | June 30, 2018 | June 30, 2018 | December 17, 2014 | January 4, 2018 | ||||
25 | NCT03787628 | Not yet recruiting | Cannabidiol as Adjunctive Treatment for Opioid Use Disorder |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
60 | All | 21 Years to 65 Years (Adult, Older Adult) | NCT03787628 | 18-001748 | March 1, 2019 | January 31, 2021 | March 31, 2021 | December 25, 2018 | December 25, 2018 | ||||
26 | NCT03549819 | Not yet recruiting | Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study |
|
|
Interventional |
Phase 3 |
|
Other / Industry |
|
|
50 | All | 21 Years to 65 Years (Adult, Older Adult) | NCT03549819 | CBD_ANX | August 2018 | August 2020 | October 2020 | June 8, 2018 | June 8, 2018 |
|
|||
27 | NCT02844933 | Recruiting | Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
66 | All | 8 Years to 17 Years (Child) | NCT02844933 | INS011-16-085 | June 6, 2018 | June 2019 | June 2019 | July 26, 2016 | February 5, 2019 |
|
|||
28 | NCT02556008 | No longer available | Cannabidiol for Pediatric Epilepsy (Compassionate Use) |
|
|
Expanded Access |
|
Other | All | 1 Year to 17 Years (Child) | NCT02556008 | SH001 | September 22, 2015 | May 3, 2017 |
|
||||||||||
29 | NCT02559167 | Recruiting | Cannabidiol and Cocaine Craving/Dependence |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
110 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT02559167 | 14.183 | CBD | February 2016 | September 2019 | December 2019 | September 24, 2015 | January 31, 2019 |
|
||
30 | NCT03196934 | Available | Expanded Use of Cannabidiol Oral Solution |
|
|
Expanded Access
|
|
Other | All | 1 Year to 18 Years (Child, Adult) | NCT03196934 | MulticareHSRI | June 23, 2017 | June 23, 2017 | |||||||||||
31 | NCT02818777 | Recruiting | A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
60 | All | 45 Years to 78 Years (Adult, Older Adult) | NCT02818777 | 15-0929 | July 2016 | December 2018 | June 2019 | June 30, 2016 | April 28, 2017 |
|
|||
32 | NCT03467620 | Not yet recruiting | Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
36 | All | 18 Years and older (Adult, Older Adult) | NCT03467620 | CBD2018 | July 2018 | July 2019 | July 2019 | March 16, 2018 | March 20, 2018 | ||||
33 | NCT03421496 | Recruiting | A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
190 | All | 1 Month to 24 Months (Child) | NCT03421496 | INS011-16-082 | September 5, 2018 | December 2019 | December 2019 | February 5, 2018 | February 5, 2019 |
|
|||
34 | NCT01605539 | Completed Has Results |
Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
10 | All | 21 Years to 65 Years (Adult, Older Adult) | NCT01605539 | R21 DA027781(2) | May 2012 | October 2013 | October 2013 | May 25, 2012 | November 28, 2016 | November 28, 2016 |
|
||
35 | NCT02902081 | Completed | Cannabidiol and Emotional Stimuli |
|
|
Interventional |
Not Applicable |
|
Other / Industry |
|
|
38 | All | 18 Years to 35 Years (Adult) | NCT02902081 | IRB13-0215 | CAS | February 2013 | March 2017 | March 2017 | September 15, 2016 | June 1, 2017 |
|
||
36 | NCT03518801 | Not yet recruiting | Cannabidiol and Prolonged Exposure |
|
|
Interventional |
Phase 2 |
|
U.S. Fed / Other |
|
|
136 | All | 18 Years and older (Adult, Older Adult) | NCT03518801 | MHBB-001-17F | CBD-PE | February 11, 2019 | September 30, 2023 | September 30, 2023 | May 8, 2018 | February 6, 2019 |
|
||
37 | NCT02318602 | Completed Has Results |
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
52 | All | 1 Year to 18 Years (Child, Adult) | NCT02318602 | INS011-14-030 | January 8, 2016 | June 22, 2017 | June 22, 2017 | December 17, 2014 | July 25, 2018 | July 25, 2018 |
|
||
38 | NCT02783092 | Recruiting | A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy |
|
|
Interventional |
Phase 3 |
|
Other / Industry |
|
|
126 | All | 2 Years to 18 Years (Child, Adult) | NCT02783092 | CBD-PRATI-USP_01 | November 9, 2018 | August 2020 | December 2020 | May 26, 2016 | November 27, 2018 |
|
|||
39 | NCT02392780 | Unknown † | Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
10 | All | 18 Years and older (Adult, Older Adult) | NCT02392780 | 0009-15-RMC | April 2015 | April 2018 | March 19, 2015 | March 19, 2015 |
|
||||
40 | NCT01844687 | Completed Has Results |
Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana |
|
|
Interventional |
Phase 2 |
|
NIH |
|
|
50 | All | 18 Years to 50 Years (Adult) | NCT01844687 | Study Number CBD-001 | May 2013 | October 2014 | October 2014 | May 1, 2013 | April 25, 2017 | April 25, 2017 |
|
||
41 | NCT03215940 | Recruiting | Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC) |
|
|
Interventional |
Early Phase 1 |
|
Other |
|
|
75 | All | 18 Years to 50 Years (Adult) | NCT03215940 | IRB_00103451 | February 1, 2018 | October 2019 | December 2019 | July 12, 2017 | January 9, 2019 |
|
|||
42 | NCT02088060 | Active, not recruiting | A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
150 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT02088060 | CBD-FEP 2012-004335-23 |
March 2014 | August 2021 | December 2021 | March 14, 2014 | March 8, 2018 |
|
|||
43 | NCT02461706 | No longer available | Treatment of Drug Resistant Epilepsy |
|
|
Expanded Access |
|
Other | All | 2 Years to 16 Years (Child) | NCT02461706 | IRB201401013 FLGV |
Cannabidiol | June 3, 2015 | January 21, 2019 |
|
|||||||||
44 | NCT02953548 | Active, not recruiting | Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
10 | All | 1 Month to 24 Months (Child) | NCT02953548 | GWEP15100 Pilot Phase 2015-004904-50 |
March 16, 2017 | October 2018 | October 2018 | November 2, 2016 | July 17, 2018 |
|
|||
45 | NCT02224703 | Unknown † | GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
150 | All | 2 Years to 18 Years (Child, Adult) | NCT02224703 | GWEP1424 2014-002939-34 |
March 2015 | May 2017 | June 2017 | August 25, 2014 | October 12, 2016 |
|
|||
46 | NCT02051387 | Completed | Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
74 | All | 18 Years to 45 Years (Adult) | NCT02051387 | CBD-IS 2008-008245-38 |
CBD-IS | January 2013 | August 2017 | August 2017 | January 31, 2014 | March 8, 2018 |
|
||
47 | NCT02954887 | Active, not recruiting | Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
202 | All | 1 Month to 24 Months (Child) | NCT02954887 | GWEP15100 Open-label Extension 2015-004904-50 |
May 9, 2017 | December 2018 | December 2018 | November 4, 2016 | July 16, 2018 |
|
|||
48 | NCT03582137 | Recruiting | A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
75 | All | 40 Years to 85 Years (Adult, Older Adult) | NCT03582137 | 17-2318 | September 17, 2018 | December 2019 | June 2020 | July 10, 2018 | January 21, 2019 |
|
|||
49 | NCT02044809 | Completed | Cannabidiol: a Novel Intervention for Cannabis Use Problems? |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
82 | All | 16 Years to 60 Years (Child, Adult) | NCT02044809 | 12/0278 | March 2014 | February 9, 2017 | June 5, 2017 | January 24, 2014 | October 24, 2018 |
|
|||
50 | NCT02478424 | Unknown † | Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
10 | All | 18 Years and older (Adult, Older Adult) | NCT02478424 | RMC-0208-14 | July 2015 | December 2016 | June 2017 | June 23, 2015 | June 23, 2015 | ||||
51 | NCT02910297 | Withdrawn | The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy |
|
Observational |
|
Other |
|
|
0 | All | 2 Years to 30 Years (Child, Adult) | NCT02910297 | CBD-PK-1 | September 2016 | December 31, 2017 | December 31, 2017 | September 22, 2016 | February 21, 2018 | ||||||
52 | NCT00309413 | Completed | A Clinical Trial on the Antipsychotic Properties of Cannabidiol |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
29 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT00309413 | CBD-PT 04-153 | March 2006 | March 2008 | July 2008 | March 31, 2006 | July 25, 2008 |
|
|||
53 | NCT02083874 | Unknown † | Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
5 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT02083874 | NCPIC2014001 | March 2014 | September 2014 | December 2014 | March 11, 2014 | March 11, 2014 | ||||
54 | NCT02224573 | Enrolling by invitation | GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
680 | All | 2 Years and older (Child, Adult, Older Adult) | NCT02224573 | GWEP1415 2014-001834-27 |
June 2015 | June 2019 | June 2019 | August 25, 2014 | October 24, 2017 | ||||
55 | NCT02926859 | Recruiting | Enhancing Recovery in Early Schizophrenia |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
180 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT02926859 | CBD-ESPRIT | April 8, 2017 | March 2019 | March 2019 | October 6, 2016 | January 8, 2019 |
|
|||
56 | NCT02504151 | Active, not recruiting | Cannabidiol Treatment in Patients With Early Psychosis |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
72 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT02504151 | 1412015000 | CBD | August 2015 | August 2019 | December 2019 | July 21, 2015 | October 15, 2018 |
|
||
57 | NCT02224690 | Completed Has Results |
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
171 | All | 2 Years to 55 Years (Child, Adult) | NCT02224690 | GWEP1423 2014-002941-23 |
GWPCARE4 | April 28, 2015 | March 18, 2016 | March 18, 2016 | August 25, 2014 | July 27, 2018 | July 27, 2018 |
|
|
58 | NCT02447198 | Completed | Cannabidiol (CBD) and Pediatric Epilepsy |
|
Observational |
|
Other |
|
|
42 | All | 31 Days to 17 Years (Child) | NCT02447198 | 15-0216 UL1TR001082 |
November 2, 2015 | September 11, 2018 | September 11, 2018 | May 18, 2015 | October 30, 2018 |
|
|||||
59 | NCT03024827 | Recruiting | Cannabidiol in Children With Refractory Epileptic Encephalopathy |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
28 | All | 1 Year to 10 Years (Child) | NCT03024827 | CARE-E-01 | CARE-E | April 26, 2017 | July 2019 | December 2019 | January 19, 2017 | October 15, 2018 |
|
||
60 | NCT02564952 | Completed Has Results |
An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
18 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT02564952 | GWEP1428 Open-Label Extension 2014-002942-33 |
March 11, 2016 | June 7, 2017 | June 7, 2017 | October 1, 2015 | September 11, 2018 | September 11, 2018 |
|
||
61 | NCT01893424 | Completed | Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol) |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
12 | Male | 18 Years to 45 Years (Adult) | NCT01893424 | 0658-12-HMO-CTIL | August 2013 | January 2014 | January 2015 | July 9, 2013 | March 24, 2016 |
|
|||
62 | NCT03295903 | Not yet recruiting | Cannabinoid Supplementation on Vascular and Cognitive Function |
|
|
Interventional |
Early Phase 1 |
|
Other / Industry |
|
|
24 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03295903 | H17-01957 | October 2017 | July 2019 | August 2019 | September 28, 2017 | September 28, 2017 |
|
|||
63 | NCT02544763 | Active, not recruiting | A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
210 | All | 1 Year to 65 Years (Child, Adult, Older Adult) | NCT02544763 | GWEP1521 Blinded Phase 2015-002154-12 |
April 2016 | February 2019 | February 2019 | September 9, 2015 | September 26, 2018 |
|
|||
64 | NCT00588731 | Completed Has Results |
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
41 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT00588731 | 0710003164 07TGS-1082 |
February 2009 | December 2013 | December 2013 | January 9, 2008 | June 8, 2017 | June 8, 2017 |
|
||
65 | NCT00628290 | Completed | Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
42 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT00628290 | CBD-CT1 SMRI Grant ID: 00-093 |
CBD-CT1 | October 2002 | November 2004 | March 2008 | March 5, 2008 | March 18, 2008 |
|
||
66 | NCT02544750 | Enrolling by invitation | An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
210 | All | 1 Year to 65 Years (Child, Adult, Older Adult) | NCT02544750 | GWEP1521 Open-Label Extension 2015-002154-12 |
August 2016 | February 2022 | February 2022 | September 9, 2015 | October 1, 2018 |
|
|||
67 | NCT02291536 | Completed | Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD) |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
20 | Male | 18 Years to 65 Years (Adult, Older Adult) | NCT02291536 | AB_THC_CBD | AB_THC_CBD | February 2014 | December 2014 | December 2014 | November 14, 2014 | January 16, 2015 |
|
||
68 | NCT02777502 | Recruiting | Effects of Cannabidiol on Marijuana-seeking in Humans |
|
Observational |
|
Other |
|
|
25 | All | 21 Years to 45 Years (Adult) | NCT02777502 | CBD-1 | January 1, 2016 | December 2018 | December 2018 | May 19, 2016 | October 4, 2018 |
|
|||||
69 | NCT02565108 | Completed Has Results |
A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
20 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT02565108 | GWEP1428 Blinded Phase 2014-002942-33 |
January 20, 2016 | July 21, 2016 | July 21, 2016 | October 1, 2015 | August 23, 2018 | August 23, 2018 |
|
||
70 | NCT01180374 | Active, not recruiting | The Effects of Cannabidiol and ∆-9-THC in Humans |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
75 | All | 18 Years to 55 Years (Adult) | NCT01180374 | 1001006240 | June 2010 | July 2019 | July 2019 | August 12, 2010 | June 6, 2018 |
|
|||
71 | NCT02987114 | Completed | A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
16 | All | 2 Years to 15 Years (Child) | NCT02987114 | CS-100 | February 13, 2017 | June 28, 2018 | June 28, 2018 | December 8, 2016 | September 6, 2018 |
|
|||
72 | NCT02091375 | Completed Has Results |
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
120 | All | 2 Years to 18 Years (Child, Adult) | NCT02091375 | GWEP1332 Part B 2014-002941-23 |
March 30, 2015 | November 26, 2015 | November 26, 2015 | March 19, 2014 | August 27, 2018 | July 20, 2018 |
|
||
73 | NCT03840512 | Recruiting New |
An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD) |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
36 | All | 18 Years and older (Adult, Older Adult) | NCT03840512 | KAL05 | August 1, 2018 | October 15, 2019 | November 15, 2019 | February 15, 2019 | February 15, 2019 |
|
|||
74 | NCT02695537 | Active, not recruiting | Safety, and Tolerability of Epidiolex In Patients ((Ages 1 - 19 Years) With Intractable Epilepsy |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
100 | All | 1 Year to 18 Years (Child, Adult) | NCT02695537 | IND# 124160 | April 2015 | February 2020 | February 2020 | March 1, 2016 | November 30, 2018 |
|
|||
75 | NCT02397863 | Available | Epidiolex and Drug Resistant Epilepsy in Children |
|
|
Expanded Access |
|
Other | All | 1 Year to 18 Years (Child, Adult) | NCT02397863 | CBD02 | CBD | December 2014 | December 2019 | January 2020 | March 25, 2015 | April 24, 2015 |
|
||||||
76 | NCT02607891 | Recruiting | A Study to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
40 | All | 16 Years to 55 Years (Child, Adult) | NCT02607891 | GWEP1447 Blinded Phase 2015-002939-18 |
October 2016 | August 2018 | August 2018 | November 18, 2015 | November 1, 2017 |
|
|||
77 | NCT03003260 | Unknown † | The Effect of CanChew® Cannabidiol (CBD) Containing Chewing Gum on Irritable Bowel Syndrome |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
40 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT03003260 | NL58588.081.16 | December 2016 | April 2017 | June 2017 | December 26, 2016 | December 26, 2016 |
|
|||
78 | NCT03825965 | Not yet recruiting New |
Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT03825965 | Cannabis TKA Pilot Trial | April 2019 | April 2021 | April 2021 | February 1, 2019 | February 1, 2019 |
|
|||
79 | NCT02291562 | Completed | Effects of THC and CBD on Human Episodic Memory Function |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
20 | Male | 18 Years to 50 Years (Adult) | NCT02291562 | LOGIN_EpMem | July 2014 | December 2014 | December 2014 | November 14, 2014 | January 16, 2015 |
|
|||
80 | NCT02607904 | Enrolling by invitation | An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
40 | All | 16 Years to 55 Years (Child, Adult) | NCT02607904 | GWEP1447 Open-label Extension 2015-002939-18 |
November 2016 | August 2019 | August 2019 | November 18, 2015 | November 1, 2017 | ||||
81 | NCT02751359 | Active, not recruiting | Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
18 | All | 21 Years to 50 Years (Adult) | NCT02751359 | 7009 | June 2016 | December 2018 | December 2018 | April 26, 2016 | April 9, 2018 |
|
|||
82 | NCT02700412 | Active, not recruiting | University of Alabama at Birmingham (UAB) Adult CBD Program |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
100 | All | 15 Years to 99 Years (Child, Adult, Older Adult) | NCT02700412 | IND# 124138 | April 2015 | April 2019 | April 2019 | March 7, 2016 | June 29, 2018 |
|
|||
83 | NCT02224560 | Completed Has Results |
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
225 | All | 2 Years to 55 Years (Child, Adult) | NCT02224560 | GWEP1414 2014-002940-42 |
GWPCARE3 | June 8, 2015 | May 19, 2016 | May 19, 2016 | August 25, 2014 | July 27, 2018 | July 27, 2018 |
|
|
84 | NCT03607643 | Not yet recruiting | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
160 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03607643 | Olympian | January 15, 2019 | June 30, 2020 | December 15, 2020 | July 31, 2018 | July 31, 2018 |
|
|||
85 | NCT02255292 | Unknown † | A Study: Pure CBD as Single-agent for Solid Tumor. |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
60 | All | 18 Years and older (Adult, Older Adult) | NCT02255292 | CBD- HMO-CTIL | November 2014 | July 2015 | July 2015 | October 2, 2014 | October 2, 2014 | ||||
86 | NCT02539823 | Completed | Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
45 | All | 21 Years to 65 Years (Adult, Older Adult) | NCT02539823 | MSBI HSM# 087-14 | September 2015 | May 24, 2017 | May 24, 2017 | September 3, 2015 | February 21, 2018 |
|
|||
87 | NCT02492074 | Not yet recruiting | Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
60 | Male | 18 Years to 45 Years (Adult) | NCT02492074 | GEI-TCP I | April 2019 | April 2020 | May 2020 | July 8, 2015 | March 15, 2018 |
|
|||
88 | NCT02932605 | Recruiting | Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
36 | All | 16 Years to 40 Years (Child, Adult) | NCT02932605 | ABR58805 2016-003529-41 |
CANGLIA | November 3, 2017 | January 2020 | January 2020 | October 13, 2016 | June 11, 2018 |
|
||
89 | NCT03398083 | Completed | Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam |
|
|
Interventional |
Phase 1 |
|
NIH |
|
|
42 | All | 18 Years to 55 Years (Adult) | NCT03398083 | NIDA-CBD-Phase1-001 | December 4, 2017 | May 30, 2018 | May 30, 2018 | January 12, 2018 | June 14, 2018 |
|
|||
90 | NCT02091206 | Completed Has Results |
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
34 | All | 4 Years to 10 Years (Child) | NCT02091206 | GWEP1332 Part A 2014-002941-23 |
October 22, 2014 | March 9, 2015 | March 9, 2015 | March 19, 2014 | August 24, 2018 | July 19, 2018 |
|
||
91 | NCT03802799 | Recruiting | Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS |
|
|
Interventional |
Phase 2 Phase 3 |
|
Industry |
|
|
300 | All | 3 Years to 18 Years (Child, Adult) | NCT03802799 | ZYN2-CL-017 | November 9, 2018 | September 30, 2019 | September 30, 2020 | January 14, 2019 | January 14, 2019 |
|
|||
92 | NCT03614663 | Recruiting | Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) |
|
|
Interventional |
Phase 2 Phase 3 |
|
Industry |
|
|
204 | All | 3 Years to 17 Years (Child) | NCT03614663 | ZYN2-CL-016 | CONNECT-FX | June 12, 2018 | July 23, 2019 | October 29, 2019 | August 3, 2018 | January 17, 2019 |
|
||
93 | NCT03693833 | Recruiting | CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis. |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
180 | All | 18 Years and older (Adult, Older Adult) | NCT03693833 | NordCAN | NordCAN | October 20, 2018 | October 1, 2019 | December 31, 2019 | October 3, 2018 | January 24, 2019 |
|
||
94 | NCT02983695 | Active, not recruiting | Cannabinoid Therapy for Pediatric Epilepsy |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
20 | All | 1 Year to 18 Years (Child, Adult) | NCT02983695 | 1000047417 | February 2, 2017 | August 24, 2018 | October 31, 2019 | December 6, 2016 | February 5, 2019 |
|
|||
95 | NCT01284634 | Completed Has Results |
Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
25 | All | 18 Years and older (Adult, Older Adult) | NCT01284634 | GWMD09112 2009-017080-41 |
May 3, 2011 | July 13, 2012 | July 13, 2012 | January 27, 2011 | August 8, 2018 | January 20, 2014 |
|
||
96 | NCT03537950 | Active, not recruiting | Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
38 | Male | 18 Years to 50 Years (Adult) | NCT03537950 | HR15-162744 | August 22, 2016 | February 16, 2017 | April 27, 2019 | May 25, 2018 | May 25, 2018 |
|
|||
97 | NCT02487381 | Completed | Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
60 | Male | 18 Years to 45 Years (Adult) | NCT02487381 | GEI-TCP II | April 2015 | July 2015 | August 2015 | July 1, 2015 | August 17, 2015 |
|
|||
98 | NCT03832816 | Not yet recruiting New |
Behavioral and Physiological Effects of THC and CBD |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
120 | All | 18 Years to 50 Years (Adult) | NCT03832816 | IRB00199386 | May 2019 | May 2021 | May 2021 | February 6, 2019 | February 6, 2019 |
|
|||
99 | NCT02815540 | Unknown † | The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
25 | All | 2 Years to 30 Years (Child, Adult) | NCT02815540 | CBD-001 | CBD1 | June 2016 | June 2017 | December 2017 | June 28, 2016 | June 28, 2016 |
|
||
100 | NCT01887301 | Completed | Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
32 | All | 18 Years and older (Adult, Older Adult) | NCT01887301 | GWCP10114 | July 2013 | May 2014 | May 2014 | June 26, 2013 | June 4, 2014 |
|
† Study has passed its completion date and status has not been verified in more than two years.